Akribion Genomics

Akribion Genomics, which operates under the legal entity Akribion Therapeutics, is a biotechnology company developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Using its proprietary G-dase® E payload, the company's platform works by shredding DNA and RNA only when a highly specific match occurs between a guide RNA and an intracellular RNA sequence. This mechanism allows for precise differentiation between targeted and healthy cells, offering a modular and flexible approach where new targets can be addressed simply by exchanging the guide RNA. Originally spun out of BRAIN Biotech AG, the company leverages this nuclease technology to innovate in the field of precision oncology and beyond.

The technology is primarily aimed at addressing significant medical needs, with an initial focus on HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC). By providing a highly specific and adaptable platform, Akribion aims to develop faster, more effective therapeutic alternatives compared to traditional methods. Beyond oncology, the company is actively exploring applications in autoimmune diseases, fibrosis, and infectious diseases. Supported by institutional venture financing, the company works to advance these novel therapeutics while maintaining a commitment to high ethical standards in the development of its CRISPR-based genome editing tools and genetic medicine solutions.